Related Experiment Video
Updated: Jul 26, 2025

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Multiscale modeling of HBV infection integrating intra- and intercellular viral propagation for analyzing
Kosaku Kitagawa1, Kwang Su Kim1,2, Masashi Iwamoto1,3
1interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University; Nagoya, Japan.
Insights
A new mathematical model non-invasively quantifies hepatitis B virus (HBV) cccDNA in the liver using blood markers. This breakthrough aids in developing better chronic HBV treatments and understanding infection dynamics.
Area of Science:
- Hepatology
- Mathematical Biology
- Virology
Background:
- Chronic hepatitis B virus (HBV) infection is driven by persistent nuclear HBV cccDNA in hepatocytes.
- Current methods to quantify intrahepatic HBV cccDNA require invasive liver biopsies, limiting clinical application.
- Eliminating HBV cccDNA is crucial for effective chronic HBV treatment, yet remains a significant therapeutic challenge.
Approach:
- Developed a multiscale mathematical model integrating intracellular and intercellular HBV infection dynamics using age-structured partial differential equations.
- The model incorporates in vitro and in vivo experimental data for comprehensive HBV infection process representation.
- Validated the model by predicting intrahepatic HBV cccDNA levels and dynamics from peripheral blood viral markers (HBV DNA, HBsAg, HBeAg, HBcrAg).
Key Points:
- Successfully established a non-invasive method to quantify intrahepatic HBV cccDNA using serum viral markers.
- Demonstrated the model's capability to predict HBV cccDNA amount and dynamics, offering insights into infection progression.
- The study provides a robust framework for understanding HBV infection and advancing therapeutic strategies.
Conclusions:
- The developed non-invasive methodology offers a promising approach for improved clinical analysis of chronic HBV infection.
- This mathematical model facilitates a deeper understanding of HBV infection dynamics and the role of cccDNA.
- The findings pave the way for developing targeted interventions and novel anti-HBV drug discovery.
Abstract:
Chronic infection of hepatitis B virus (HBV) is caused by the persistence of closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. Despite available therapeutic anti-HBV agents, eliminating the cccDNA remains challenging. The quantifying and understanding dynamics of cccDNA are essential for developing effective treatment strategies and new drugs. However, it requires a liver biopsy to measure the intrahepatic cccDNA, which is basically not accepted because of the ethical aspect. We here aimed to develop a non-invasive method for quantifying cccDNA in the liver using surrogate markers present in peripheral blood. We constructed a multiscale mathematical model that explicitly incorporates both intracellular and intercellular HBV infection processes. The model, based on age-structured partial differential equations (PDEs), integrates experimental data from in vitro and in vivo investigations. By applying this model, we successfully predicted the amount and dynamics of intrahepatic cccDNA using specific viral markers in serum samples, including HBV DNA, HBsAg, HBeAg, and HBcrAg. Our study represents a significant step towards advancing the understanding of chronic HBV infection. The non-invasive quantification of cccDNA using our proposed methodology holds promise for improving clinical analyses and treatment strategies. By comprehensively describing the interactions of all components involved in HBV infection, our multiscale mathematical model provides a valuable framework for further research and the development of targeted interventions.
More Related Videos
11:14Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022